Thymosin Alpha-1 Plus Immunotherapy Shrinks Treatment-Resistant Triple-Negative Breast Cancer: A Case Report
A woman with metastatic triple-negative breast cancer that had failed surgery, chemo, and radiation saw nearly 79% tumor shrinkage with a combination of immunotherapy, radiation, GM-CSF, and thymosin alpha-1.
Quick Facts
What This Study Found
The combination of PD-1 inhibitor, SBRT, GM-CSF, and thymosin alpha-1 produced a 78.97% regression in the target lesion and 56.73% regression in non-irradiated observed lesions (abscopal effect) in a patient with treatment-resistant mTNBC.
Key Numbers
48-year-old female patient who had not responded to multiple lines of therapy including surgery, chemotherapy, and radiotherapy.
How They Did This
Single case report from a clinical trial combining stereotactic body radiotherapy (SBRT), PD-1 inhibitor immunotherapy, GM-CSF, and thymosin alpha-1. Response assessed using RECIST v1.1 criteria after 2 treatment cycles.
Why This Research Matters
Triple-negative breast cancer with metastases has very few effective treatment options. This case demonstrates that combining immune-boosting peptides like thymosin alpha-1 with immunotherapy and targeted radiation may overcome treatment resistance, especially through abscopal effects on distant tumors.
The Bigger Picture
Immunotherapy alone often fails in triple-negative breast cancer. Adding immune modulators like thymosin alpha-1 and GM-CSF alongside focused radiation may prime the immune system more effectively, producing responses in patients who have run out of standard options. The abscopal effect — where untreated tumors also shrink — suggests the combination created a systemic immune response against the cancer.
What This Study Doesn't Tell Us
Single case report — the weakest form of clinical evidence. One dramatic response does not prove the regimen works for other patients. No control group, blinding, or statistical analysis possible. The clinical trial is ongoing and broader results are needed.
Questions This Raises
- ?Will these results hold up in a larger controlled trial with more mTNBC patients?
- ?Which component of the four-drug combination is most critical for the abscopal effect?
- ?How long will this treatment response last, and will the cancer eventually develop resistance?
Trust & Context
- Key Stat:
- 79% tumor shrinkage in a triple-negative breast cancer patient who had failed all standard treatments, after adding thymosin alpha-1 to immunotherapy
- Evidence Grade:
- Preliminary evidence: single case report from a clinical trial. While the response is dramatic, case reports cannot establish treatment efficacy — larger trials are essential.
- Study Age:
- Published in 2024. Reports on a recent clinical trial combination regimen.
- Original Title:
- PD-1 inhibitor combined with SBRT, GM-CSF, and thymosin alpha-1 in metastatic breast cancer: A case report and literature review.
- Published In:
- Medicine, 103(34), e39271 (2024)
- Authors:
- Yu, Jiamin(2), Wang, Qiang(3), Wang, Lijun(3), Zong, Dan, He, Xia
- Database ID:
- RPEP-09613
Evidence Hierarchy
Frequently Asked Questions
What is thymosin alpha-1 and how does it help fight cancer?
Thymosin alpha-1 is a peptide that boosts immune function by activating T cells and other immune components. In this combination, it may help the immune system recognize and attack cancer cells more effectively alongside immunotherapy.
What is an abscopal effect?
The abscopal effect is when radiation treatment on one tumor causes untreated tumors elsewhere in the body to also shrink. It happens when radiation triggers an immune response that spreads systemically to attack cancer at other sites.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09613APA
Yu, Jiamin; Wang, Qiang; Wang, Lijun; Zong, Dan; He, Xia. (2024). PD-1 inhibitor combined with SBRT, GM-CSF, and thymosin alpha-1 in metastatic breast cancer: A case report and literature review.. Medicine, 103(34), e39271. https://doi.org/10.1097/MD.0000000000039271
MLA
Yu, Jiamin, et al. "PD-1 inhibitor combined with SBRT, GM-CSF, and thymosin alpha-1 in metastatic breast cancer: A case report and literature review.." Medicine, 2024. https://doi.org/10.1097/MD.0000000000039271
RethinkPeptides
RethinkPeptides Research Database. "PD-1 inhibitor combined with SBRT, GM-CSF, and thymosin alph..." RPEP-09613. Retrieved from https://rethinkpeptides.com/research/yu-2024-pd1-inhibitor-combined-with
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.